Search

everythinglearnresearchcommunity

for

Search:↓

All women with significant unwanted hair growth have hormonal imbalances, often from polycystic ovary syndrome.

Most women with excessive hair growth have a hormonal cause.

The 2003 consensus updated PCOS diagnosis criteria and highlighted increased risks of diabetes and heart disease for those affected.

Polycystic Ovary Syndrome should be seen mainly as a condition of excess male hormones, with a focus on this in its definition.

The report concludes that PCOS is mainly a condition of excess male hormones and its definition may change as new information is discovered.

CDP is crucial for lung and hair follicle cell development.

Flutamide is more effective and has fewer side effects than spironolactone for treating hirsutism.

Cyproterone acetate-estrogen most effective for hirsutism, but consider side effects and patient needs.

Researchers identified genes linked to coat color, body size, cashmere production, and high altitude adaptation in goats.

Amenorrhea is relatively rare and initial testing should check FSH, TSH, and prolactin levels.

Myo-inositol may be more effective than metformin for inducing ovulation in women with PCOS.

Nonionic liposomes are the best for delivering genes to skin cells.

Finasteride reduces hair loss and treats BPH without major hormone changes, but may cause sexual dysfunction.

Different types of PCOS have different levels of metabolic problems, with the most severe type showing the highest disturbances.

Women with PCOS often have hair loss, which is linked to acne or excess body hair but not to worse hormone or metabolic issues.

COVID-19 might affect male fertility, but more research is needed to understand the full impact.

Women with PCOS are more likely to have insulin resistance and obesity, especially those with the most severe type I PCOS.

GLI2 increases follistatin production in human skin cells.

The document concludes that identifying the cause of amenorrhea is crucial for proper treatment.

Natural molecules like inositols, resveratrol, vitamins, and omega-3 fatty acids may help manage Polycystic Ovary Syndrome (PCOS), but their effects vary and need more exploration.

The study found no link between baldness patterns and androgen levels in men with benign prostate enlargement or prostate cancer.

Amenorrhea is when a woman doesn't have periods, with primary amenorrhea starting by age 15 or within five years of breast development, and secondary amenorrhea when periods stop for three months. It affects 3-4% of women not pregnant, breastfeeding, or in menopause, mainly due to polycystic ovary syndrome, hypothalamic amenorrhea, hyperprolactinemia, and ovarian failure.

Immune cells affect hair growth and could lead to new hair loss treatments.

Finasteride significantly reduces hair growth in women with idiopathic hirsutism.

PBX1 helps hair stem cells grow and change by turning on certain cell signals and preventing cell death, which may be useful for hair regrowth treatments.

Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.

All treatments reduce hair growth; low dose flutamide most effective with fewer side effects.

Women with PCOS, especially those overweight, have higher levels of IL-18 in their endometrium, which may affect fertility.

Greek women with PCOS have a higher risk of metabolic syndrome and are more likely to be overweight compared to healthy controls.

Amenorrhea, or the absence of periods, should be evaluated by age 15 or within five years of early breast development, and is most commonly caused by conditions like polycystic ovary syndrome and hypothalamic amenorrhea.